#Australia #Melbourne #Avecho Biotechnology #insomnia treatment #CBD capsule

Avecho Biotechnology Advances its Phase III Insomnia Trial

MELBOURNE, Australia, June 29, 2026 – Avecho Biotechnology Limited (ASX: AVE), a company specializing in innovative biopharmaceuticals, has announced a significant development regarding its Phase III insomnia program. Following a positive interim analysis of the world's first TPM®-enhanced cannabidiol (CBD) capsule, the company has decided to proceed with the recruitment of participants. This step is crucial in validating the efficacy of their product in managing insomnia, a widespread condition affecting countless individuals globally.

In a notable achievement for Avecho, the independent Data Monitoring Board (DMB)—comprised of experts in the fields of sleep medicine, clinical safety, and biostatistics—has completed their review of the interim analysis data from the pivotal Phase III trial. The DMB unanimously recommended that the trial continue to its full enrollment of 519 participants, signifying a strong endorsement of the ongoing study's protocols and objectives. This recommendation serves as a reassuring signal, reducing clinical development risks and outlining a clear path towards the eventual completion of this critical research.

Avecho's CEO, Dr. Paul Gavin, expressed excitement about the DMB's recommendations. He stated, “This is an important and major milestone for Avecho, and exactly the outcome we designed this trial to achieve.” Dr. Gavin emphasized the robust design of the trial, which includes two independent endpoints and stringent criteria for patient inclusion. This meticulous approach aims to minimize placebo effects and maximize the understanding of the CBD capsule's true impact on insomnia.

While the study is still in progress and the final outcomes remain to be determined, early indications have left the team optimistic about the potential effectiveness of their product as a treatment for insomnia. The interim analysis utilized data from 244 participants, who were randomized into three treatment groups—receiving either nightly doses of 150 mg CBD, 75 mg CBD, or a placebo—over an eight-week period. Notably, the interim safety data also reinforced the program's promising trajectory. No serious adverse events were reported among the participants, underscoring the tolerability of the CBD capsules, which is critical to Avecho’s commercial strategy.

Looking ahead, the company's focus is shifting towards the commercial aspects of the CBD capsule. Dr. Gavin mentioned the importance of positioning their product against current sleep medications, many of which are associated with unwanted side effects such as next-day impairment or overdose risks—issues that cannabidiol does not share. With safety and efficacy at the forefront, Avecho believes that a product capable of enhancing sleep without such burdens holds a substantial market potential.

About Avecho’s Phase III Trial Program

Avecho’s Phase III clinical trial represents one of the largest studies of its kind focusing on cannabidiol, taking place at several sites across Australia. By garnering insights from both local and international sleep and regulatory experts, the trial is meticulously designed to adhere to the demanding requirements set forth by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). The trial participants will be monitored using validated questionnaires and daily sleep diaries to accurately assess their sleep quality and duration over the course of the study.

As further endorsement of its viability, last year Avecho signed a licensing agreement with Sandoz, granting commercial rights to the CBD TPM capsule in Australia. This partnership included a $3 million upfront payment alongside the prospect of significant development and commercial milestone payments, plus tiered royalties based on future sales. The favorable interim analysis strengthens Avecho's position in ongoing licensing discussions aimed at territories beyond Australia, making securing additional regional agreements a strategic priority for the company.

As Avecho looks to enhance the product's commerciality, the next steps will focus on engaging with the FDA and other regulatory bodies to chart a path forward for the CBD capsule in various international markets. The company is excited about the prospects and is actively seeking to further fund development while maximizing value for its shareholders.